Finally, with known socioeconomic inequalities in the use of GLP-1 RA as treatment for T2D [28], the study group had higher socioeconomic status compared to the standard MBS group in Sweden [29], limiting generalizability to a wider group of patients with severe obesity and T2D. The gene discussed is GCG; the disease is obesity disorder.